JP2022532918A5 - - Google Patents
Info
- Publication number
- JP2022532918A5 JP2022532918A5 JP2021568893A JP2021568893A JP2022532918A5 JP 2022532918 A5 JP2022532918 A5 JP 2022532918A5 JP 2021568893 A JP2021568893 A JP 2021568893A JP 2021568893 A JP2021568893 A JP 2021568893A JP 2022532918 A5 JP2022532918 A5 JP 2022532918A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- branched
- linear
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025150534A JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850098P | 2019-05-20 | 2019-05-20 | |
| US62/850,098 | 2019-05-20 | ||
| PCT/US2020/033615 WO2020236825A2 (en) | 2019-05-20 | 2020-05-19 | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025150534A Division JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532918A JP2022532918A (ja) | 2022-07-20 |
| JP2022532918A5 true JP2022532918A5 (https=) | 2023-07-13 |
| JP7743312B2 JP7743312B2 (ja) | 2025-09-24 |
Family
ID=70978687
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568893A Active JP7743312B2 (ja) | 2019-05-20 | 2020-05-19 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| JP2021568870A Active JP7663514B2 (ja) | 2019-05-20 | 2020-05-19 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| JP2025150534A Pending JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568870A Active JP7663514B2 (ja) | 2019-05-20 | 2020-05-19 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| JP2025150534A Pending JP2025183333A (ja) | 2019-05-20 | 2025-09-10 | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20230092679A1 (https=) |
| EP (2) | EP3972649A2 (https=) |
| JP (3) | JP7743312B2 (https=) |
| KR (2) | KR20220024106A (https=) |
| CN (2) | CN114728077A (https=) |
| AR (1) | AR122270A1 (https=) |
| AU (2) | AU2020279230A1 (https=) |
| BR (1) | BR112021023229A2 (https=) |
| CA (2) | CA3136088A1 (https=) |
| CL (1) | CL2021003042A1 (https=) |
| CO (1) | CO2021016552A2 (https=) |
| DO (1) | DOP2021000238A (https=) |
| GE (2) | GEP20257822B (https=) |
| IL (2) | IL288110A (https=) |
| JO (1) | JOP20210289A1 (https=) |
| MX (1) | MX2021014094A (https=) |
| PE (1) | PE20220218A1 (https=) |
| PH (1) | PH12021552831A1 (https=) |
| PY (1) | PY2020118A (https=) |
| SG (1) | SG11202112056PA (https=) |
| TW (1) | TW202100184A (https=) |
| UY (1) | UY38700A (https=) |
| WO (2) | WO2020236825A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4087580A4 (en) * | 2020-01-07 | 2024-01-17 | Purdue Research Foundation | TARGETED STEROID COMPOUNDS |
| SI4153242T1 (sl) * | 2020-05-19 | 2024-07-31 | Les Laboratoires Servier | Para-amino-benzilni linkerji, postopek za njihovo pripravo in njihova uporaba v konjugatih |
| WO2022093800A2 (en) | 2020-10-27 | 2022-05-05 | Elucida Oncology, Inc. | Carrier particle-drug conjugates, self-immolative linkers, and uses thereof |
| AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| IL303079A (en) * | 2020-11-24 | 2023-07-01 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| WO2022266491A1 (en) * | 2021-06-18 | 2022-12-22 | University Of Maryland, Baltimore | Proteolysis targeting chimeras and polypharmacological agents targeting bcl-2, and methods of use thereof |
| US20230212181A1 (en) * | 2022-01-01 | 2023-07-06 | Aarvik Therapeutics, Inc. | Double payload cancer therapeutics |
| US20260061065A1 (en) | 2022-05-20 | 2026-03-05 | Novartis Ag | Antibody drug conjugates |
| US20250387504A1 (en) | 2022-05-20 | 2025-12-25 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| AU2023279443A1 (en) * | 2022-06-03 | 2025-01-23 | Ube Corporation | Antibody-multidrug conjugate |
| WO2023234427A1 (ja) * | 2022-06-03 | 2023-12-07 | Ｕｂｅ株式会社 | 抗体・複数薬物コンジュゲート前駆体およびその合成中間体 |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| CN120475995A (zh) * | 2022-08-17 | 2025-08-12 | 隆萨销售股份有限公司 | 包含生物活性分子和可裂解接头的细胞外囊泡 |
| WO2024040075A1 (en) * | 2022-08-17 | 2024-02-22 | Lonza Sales Ag | Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker |
| KR20250080903A (ko) * | 2022-10-19 | 2025-06-05 | 멀티튜드 테라퓨틱스 인코퍼레이티드 | 항체-약물 접합체, 이의 제조 방법 및 용도 |
| EP4710944A1 (en) * | 2023-05-09 | 2026-03-18 | Shanghai Henlius Biotech, Inc. | Anti-pdl1 antibody-drug conjugate and use |
| CN121263211A (zh) * | 2023-05-09 | 2026-01-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗表皮生长因子受体(egfr)抗体-药物偶联物及其应用 |
| CN117229190A (zh) * | 2023-06-06 | 2023-12-15 | 武汉翱飞科技有限公司 | 一种马来酰亚胺型连接子及其制备方法与应用 |
| TW202523328A (zh) * | 2023-11-17 | 2025-06-16 | 美商建南德克公司 | Ｍｃｌ－１抑制劑化合物及在抗體藥物結合物中之用途 |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| CA2473144C (en) | 2002-02-05 | 2013-05-28 | Genentech, Inc. | Protein purification |
| ZA200503075B (en) | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2855520B1 (en) | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
| US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
| ES2732574T3 (es) | 2012-11-30 | 2019-11-25 | Novartis Ag | Métodos para preparar conjugados a partir de proteínas que contienen disulfuro |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| EP2953976B1 (en) | 2013-02-08 | 2021-03-24 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| ES2671516T3 (es) | 2013-02-19 | 2018-06-06 | Novartis Ag | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno |
| US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| ES2701051T3 (es) * | 2013-03-15 | 2019-02-20 | Novartis Ag | Conjugados de anticuerpo-fármaco |
| FR3008975A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2015095227A2 (en) * | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2017509337A (ja) | 2014-03-12 | 2017-04-06 | ノバルティス アーゲー | イムノコンジュゲートを作製する抗体を修飾するための特定部位 |
| SG11201607339VA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| TW201625692A (zh) * | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| CN111620861A (zh) | 2014-12-09 | 2020-09-04 | 艾伯维公司 | 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物 |
| CN113209306A (zh) | 2014-12-09 | 2021-08-06 | 艾伯维公司 | 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物 |
| CN107207553A (zh) | 2014-12-09 | 2017-09-26 | 艾伯维公司 | Bcl‑xl抑制性化合物和包括其的抗体药物缀合物 |
| US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3165536A1 (en) * | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US11306107B2 (en) | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| ES2791319T3 (es) | 2016-04-22 | 2020-11-03 | Astrazeneca Ab | Inhibidores de MCL1 macrocíclicos para tratar el cáncer |
| BR112018075639A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | conjugados de anticorpo fármaco anti-egfr |
| WO2017214462A2 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| AU2017279550A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| AU2017277534A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
| RU2018147224A (ru) | 2016-06-08 | 2020-07-14 | Эббви Инк. | Конъюгаты антитела к egfr и лекарственного средства |
| JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| MX2018015285A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
| US20200147235A1 (en) | 2016-06-08 | 2020-05-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| RU2019114863A (ru) * | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
| CA3043277A1 (en) | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Anti-cd46 antibodies and methods of use |
| WO2018098534A1 (en) * | 2016-12-02 | 2018-06-07 | Garvan Institute Of Medical Research | Methods of treating cancer and reagents thereof |
| CN110461361A (zh) * | 2017-02-10 | 2019-11-15 | 蜻蜓治疗公司 | 结合bcma、nkg2d和cd16的蛋白 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| WO2018192407A1 (zh) * | 2017-04-19 | 2018-10-25 | 四川科伦博泰生物医药股份有限公司 | 细胞毒素和偶联物、其用途和制备方法 |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| MA51447A (fr) * | 2017-08-01 | 2020-06-10 | Medimmune Llc | Conjugué anticorps monoclonal-médicament dirigé contre bcma |
| AU2018317828A1 (en) | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| US10676485B2 (en) | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| TW201920193A (zh) | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環ｍｅｌ-１抑制劑以及使用方法 |
| US20190160089A1 (en) * | 2017-10-31 | 2019-05-30 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
| MX2020012674A (es) * | 2018-05-29 | 2021-02-09 | Bristol Myers Squibb Co | Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion. |
| EP3807644A4 (en) * | 2018-06-12 | 2022-07-06 | Angiex, Inc. | ANTIBODY-OLIGONUCLEOTIDE CONJUGATES |
-
2020
- 2020-05-19 KR KR1020217041613A patent/KR20220024106A/ko active Pending
- 2020-05-19 SG SG11202112056PA patent/SG11202112056PA/en unknown
- 2020-05-19 PH PH1/2021/552831A patent/PH12021552831A1/en unknown
- 2020-05-19 EP EP20730922.0A patent/EP3972649A2/en active Pending
- 2020-05-19 WO PCT/US2020/033615 patent/WO2020236825A2/en not_active Ceased
- 2020-05-19 KR KR1020217041091A patent/KR20220017931A/ko active Pending
- 2020-05-19 AR ARP200101417A patent/AR122270A1/es unknown
- 2020-05-19 TW TW109116585A patent/TW202100184A/zh unknown
- 2020-05-19 JP JP2021568893A patent/JP7743312B2/ja active Active
- 2020-05-19 JP JP2021568870A patent/JP7663514B2/ja active Active
- 2020-05-19 US US17/613,006 patent/US20230092679A1/en active Pending
- 2020-05-19 CN CN202080052440.5A patent/CN114728077A/zh active Pending
- 2020-05-19 CA CA3136088A patent/CA3136088A1/en active Pending
- 2020-05-19 US US17/613,020 patent/US20230081720A1/en active Pending
- 2020-05-19 BR BR112021023229A patent/BR112021023229A2/pt unknown
- 2020-05-19 WO PCT/US2020/033602 patent/WO2020236817A2/en not_active Ceased
- 2020-05-19 UY UY0001038700A patent/UY38700A/es unknown
- 2020-05-19 AU AU2020279230A patent/AU2020279230A1/en active Pending
- 2020-05-19 MX MX2021014094A patent/MX2021014094A/es unknown
- 2020-05-19 EP EP20733328.7A patent/EP3972651A2/en active Pending
- 2020-05-19 CN CN202080043826.XA patent/CN114728076A/zh active Pending
- 2020-05-19 GE GEAP202015825A patent/GEP20257822B/en unknown
- 2020-05-19 PE PE2021001880A patent/PE20220218A1/es unknown
- 2020-05-19 PY PY202002020118A patent/PY2020118A/es unknown
- 2020-05-19 AU AU2020279979A patent/AU2020279979A1/en active Pending
- 2020-05-19 GE GEAP202515825A patent/GEAP202515825A/en unknown
- 2020-05-19 CA CA3138058A patent/CA3138058A1/en active Pending
-
2021
- 2021-10-27 JO JOP/2021/0289A patent/JOP20210289A1/ar unknown
- 2021-11-14 IL IL288110A patent/IL288110A/en unknown
- 2021-11-15 IL IL288117A patent/IL288117A/en unknown
- 2021-11-17 CL CL2021003042A patent/CL2021003042A1/es unknown
- 2021-11-18 DO DO2021000238A patent/DOP2021000238A/es unknown
- 2021-12-06 CO CONC2021/0016552A patent/CO2021016552A2/es unknown
-
2025
- 2025-09-10 JP JP2025150534A patent/JP2025183333A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532918A5 (https=) | ||
| JP2022533400A5 (https=) | ||
| WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
| AU2021290341B2 (en) | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups | |
| KR102914483B1 (ko) | 가교-결합된 피롤로벤조다이아제핀 이량체(pbd) 유도체 및 이의 접합체 | |
| KR102434308B1 (ko) | 아르기닌 활성 억제용 조성물 및 방법 | |
| EP3130608B1 (en) | (anti-her2 antibody)-drug conjugate | |
| CN109912683B (zh) | 一种细胞毒素分子、偶联物及其制备方法和应用 | |
| CA3016172C (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
| JP2023553808A5 (https=) | ||
| CA2921982C (en) | Novel cytotoxic agents for conjugation of drugs to cell binding molecule | |
| RU2664465C2 (ru) | Конъюгат антитело-лекарственное средство | |
| EP3604311A1 (en) | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof | |
| TWI785334B (zh) | 一種細胞結合分子-tubulysin衍生物偶聯物及其製備方法 | |
| AU2020233532B2 (en) | Antibody-drug conjugates including antibody against human DLK1, and use thereof | |
| CA2990300A1 (en) | Site specific homogeneous conjugates with ksp inhibitors | |
| CA3202759A1 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| WO2022199237A1 (zh) | 修饰的氨基酸及其在adc中的应用 | |
| JP2023553811A5 (https=) | ||
| CN105641707A (zh) | 细胞毒素分子同细胞结合受体分子的共轭体 | |
| WO2024239281A1 (en) | Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate | |
| WO2025233682A1 (en) | Antibody drug conjugates comprising sting agonists and uses thereof | |
| RU2021137408A (ru) | Конъюгаты антитело-лекарственное средство ингибитора MCL-1 и способы их применения | |
| RU2021137422A (ru) | Конъюгаты антитело-лекарственное средство ингибитора mcl-1 и способы их применения | |
| RU2801630C2 (ru) | Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение |